Age, stage, MYCN oncogene status, and DNA ploidy status were clinically relevant factors: unfavorable biologic features are older age, advanced stage, and amplified MYCN and diploid.14–16 The age-specific incidence rate for neuroblastoma under 1 year of age rapidly increased with the introduction of the screening program at 6 months of age according to calendar year analysis as well as birth cohort analysis, and the disease was more localized at a younger age, which is associated with markers of good prognosis. The gene discussed is MYCN; the disease is neuroblastoma.